Projects

Mgr. Matúš Durdík, PhD.

International

Current
  • Genomic instability in cells from persons exposed to RF from base stations
    Program: Other
    Duration: 8. 9. 2021 – 31. 12. 2027
Finished
  • Molecular Markers for Biological Dosimetry in Radiation Oncology, Cancer Risk, Assesment and Optimizing Cancer Therapy
    Program: IAEA
    Duration: 19. 9. 2017 – 9. 7. 2023

National

Current
  • Individual radiosensitivity of cancer patients and use of Gingko biloba in the prevention of radiotherapy induced side effects
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Evaluation of 5G radiation induced genotoxicity and assessment of phytochemicals as modulator of radiation induced DNA damage and cancer
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Assessment of DNA damage and genetic instability in hospital workers occupationally exposed to low doses of ionizing radiation
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Anti - tumour and anti - inflammatory properties of curcumin in cancer patients
    Program:
    Duration: 1. 8. 2024 – 30. 6. 2026
  • Radiation-induced noncoding RNAs in mononuclear cells of umbilical cord blood
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Study of genetic instability in cells from leukemic patients and chemotherapy-resistant preleukemic stem cells at remission for prevention of relapses 
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • Mechanisms of impact of low intensity electromagnetic radiation on course of cancer disease
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Biomarkers for assessment of individual radiosensitivity in breast cancer therapy
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • DNA damage REsponse and preleukemic Clones in hematopoietic stem cells in diagnOstics, Risk estimation and treatment of peDiatric leukemia
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 9. 2019
  • Constitutive and induced DNA damage in hematopoietic cells for assessment of risk and optimizing treatment of childhood leukemia
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Preleukemic gene fusions and DNA repair in umbilical cord blood cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
Employees